Discordant HER2 expression and response to neoadjuvant chemoradiotherapy in esophagogastric adenocarcinoma

BACKGROUND: Targeting human epidermal growth factor receptor 2 (HER2) with trastuzumab in metastatic esophagogastric adenocarcinoma (EGA) improves survival. The impact of HER2 inhibition in combination with chemoradiotherapy (CRT) in early stage EGA is under investigation. This study analyzed the pa...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:J Gastrointest Oncol
Hauptverfasser: Chan, Ellie, Duckworth, Lizette Vila, Alkhasawneh, Ahmad, Toro, Tania Zuluaga, Lu, Xiaomin, Ben-David, Kfir, Hughes, Steven J., Rossidis, Georgios, Zlotecki, Robert, Lightsey, Judith, Daily, Karen C., Dang, Long, Allegra, Carmen J., King, Brent, George, Thomas J.
Format: Artigo
Sprache:Inglês
Veröffentlicht: AME Publishing Company 2016
Schlagworte:
Original Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4783750/
https://ncbi.nlm.nih.gov/pubmed/27034783
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3978/j.issn.2078-6891.2015.071
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge